



Jornal de
Pediatria

www.jpmed.com.br



ORIGINAL ARTICLE

Analysis of complications related to diabetic ketoacidosis in pediatric patients at a University

Q1 Hospital: a cross-sectional study

Q2 Caroline Quilice Naccarato *, Nathalia Azevedo , Raphael Del Roio Liberatore Jr

Universidade de São Paulo (USP), Faculdade de Medicina de Ribeirão Preto (FMRP), Departamento de Pediatria - Endocrinologia
Pediátrica, Ribeirão Preto, São Paulo, Brazil

Received 9 September 2024; accepted 17 January 2025

Available online xxx

KEYWORDS

Pediatrics;
Diabetic ketoacidosis;
Type 1 diabetes
mellitus

Abstract

Objectives: Diabetic ketoacidosis is one of the main complications of type 1 diabetes mellitus and the leading cause of death among children and adolescents with the disease. The objective of this study was to characterize the cases of diabetic ketoacidosis treated in a University Hospital reference in pediatric endocrinology and identify their most frequent complications.

Methods: A cross-sectional descriptive study was carried out, based on the review of medical records of patients aged 0–16 years with a diagnosis of diabetic ketoacidosis treated between January 2016 and August 2020. Insulin therapy was performed subcutaneously as part of the hospital's protocol.

Results: Seventy-seven (77) admissions were analyzed and 55.8% were diagnosed with a new case of type 1 diabetes. Adolescents (54.5%) were the most affected. An increase of 90.9% of cases between 2016 and 2020 was visualized. Severe DKA was more frequent in school-aged children. An increase in the dose of insulin was related to the severity of diabetic ketoacidosis. Hypokalemia was the most frequent complication. Cerebral edema occurred in 11.7% of cases, and it was the cause of the only death, corresponding to a mortality rate of 1.3%.

Conclusions: Rising DKA incidence aligns with global trends, with poor adherence driving cases in previously diagnosed adolescents. High rates of hypokalemia and cerebral edema were found, but with lower mortality, showing the effectiveness of subcutaneous insulin for treatment. Future studies should confirm findings, address adherence issues, and refine hydration, insulin dosing, and monitoring practices to reduce complications.

© 2025 Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de Pediatria. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

* Corresponding author.

E-mail: carol.naccarato@hotmail.com (C.Q. Naccarato).

<https://doi.org/10.1016/j.jpmed.2025.01.009>

0021-7557/© 2025 Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de Pediatria. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Please cite this article in press as: C.Q. Naccarato, N. Azevedo and R.D. Liberatore, Analysis of complications related to diabetic ketoacidosis in pediatric patients at a University Hospital: a cross-sectional study, *Jornal de Pediatria* (2025), <https://doi.org/10.1016/j.jpmed.2025.01.009>

1 Introduction

2 Type 1 diabetes mellitus (T1DM) is one of the most prevalent
3 chronic diseases in the pediatric population,¹ characterized
4 by autoimmune destruction of pancreatic beta cells, leading
5 to total insulin deficiency.² In 2021, Brazil was in third place
6 in the world ranking of new cases of T1DM among individuals
7 aged 0–19 years old.¹ The incidence and prevalence have
8 been increasing globally, due to rising disease cases and
9 decreasing mortality.¹

10 Diabetic ketoacidosis (DKA) is a serious and potentially
11 life-threatening complication of T1DM and may be the first
12 manifestation of the disease.^{3,4} It remains the main cause of
13 death among children and adolescents with type 1 diabe-
14 tes.²⁻⁴ The highest mortality is related to the occurrence of
15 cerebral edema.^{1,5,6}

16 The Clinical Hospital of the Ribeirão Preto Medical School
17 (HC-FMRP), where the study was carried out, is a tertiary
18 care center for pediatric endocrinology and pediatric emer-
19 gencies in the XIII Regional Health Division of the state of
20 São Paulo, comprising 26 cities. It is responsible for the
21 treatment of DKA cases in the public health system. This
22 study aimed to characterize the epidemiological and clinical
23 features of pediatric DKA, evaluate its complications and
24 morbidity, and evaluate the effectiveness of the treatment
25 at the institution.

26 Materials and methods

27 This is a cross-sectional descriptive study, based on the
28 review of medical records from the Clinical Hospital of the
29 Ribeirão Preto Medical School. The patient list was obtained
30 from the Institution's Medical Archive Service, by searching
31 for hospitalizations with diabetic ketoacidosis codes from
32 ICD-10.⁷ Patients with multiple occurrences of DKA were
33 included more than once.

34 The sample included pediatric patients (0 to 16 years old,
35 which is the cutoff age for the pediatrics in this hospital)
36 with DKA treated between January 2016 and August 2020.
37 Charts from patients not meeting diagnostic criteria were
38 excluded.

39 The project was approved by the Ethics and Research
40 Committee of the HC-FMRP, by protocol number
41 5,832,639.

42 Protocol for diagnosis and treatment of DKA in this 43 service

44 The treatment of children and adolescents with DKA takes
45 place in the Emergency Unit, a hospital designated for
46 urgent and emergency cases. All children up to the age of 16
47 are treated by the pediatrics department, according to the
48 institution's protocol. Patients older than this age are
49 referred to the adult medical team. The pediatrics depart-
50 ment follows its own DKA treatment protocol, which is
51 unpublished and was developed by the leading emergency
52 doctors of the sector.

53 In this protocol, DKA is defined as blood glucose above
54 200 mg/dl; venous serum pH below 7.3 and/or serum bicar-
55 bonate below 15 mmol/L; and presence of ketonemia and
56 ketonuria.

DKA is classified as mild (pH between 7.3 and 7.2 or bicar- 57
bonate between 15 and 10 mEq/L), moderate (pH < 7.2 or 58
bicarbonate between 5 and 10 mEq/L), and severe (pH < 7.1 59
or bicarbonate < 5 mEq/L). 60

Rehydration is made by intravenous 0.9% saline solution. 61
The degree of dehydration is clinically estimated between 6 62
and 8% of body weight. Regular insulin administration starts 63
after the first hour of hydration, using subcutaneous insulin 64
therapy at a dose of 0.1 U/kg. The same dosage is adminis- 65
tered every hour until the resolution of DKA (bicarbonate 66
greater than or equal to 15 mEq/L and pH greater than or 67
equal to 7.3). The diet is started after DKA is resolved. 68

Potassium chloride is added to the IV fluids when its 69
serum level is below 6 mEq/L, with potassium infusion being 70
0.2 to 0.5 mEq/kg/h, according to the corrected potassium 71
value. Insulin therapy is not indicated in patients with potas- 72
sium levels of <3.0, requiring its replacement in higher 73
doses (0.4 to 0.5 mEq/kg/h), and insulin started only after 74
this correction. 75

The aim was to maintain blood glucose between 150 and 76
200 mg/dL, so when lower values, glucose was added to the 77
IV fluids, or half the insulin dose (0.05 U/kg) could be given 78
at certain times. Sodium bicarbonate is used only when pH 79
values below 7 are found. 80

DKA cases were managed in the pediatric emergency 81
room. Patients who need neurological monitoring (suspected 82
or confirmed cerebral edema), ventilatory support, and dif- 83
ficult-to-control electrolyte disorders were admitted to 84
Intensive Care Units. 85

86 Evaluated data

87 In reviewing the medical records, the following aspects were
88 analyzed: gender, age, type of diabetes mellitus (1 or 2),
89 time since diagnosis (onset T1DM or previous diagnosis),
90 treatment before admission to the HC-FMRP, initial tests
91 (pH, bicarbonate (HCO₃), blood glucose, sodium, potassium
92 and phosphorus), time for recovery from DKA, the volume of
93 infused solution and insulin used until recovery from acido-
94 sis, use of bicarbonate, the occurrence of complications
95 (hypokalemia, hypoglycemia, hypophosphatemia, cerebral
96 edema and death), and hospitalization in Intensive Care
97 Units. The data were schematized in tables and figures, and
98 it was calculated means, standard deviation, and frequen-
99 cies using Microsoft Office Excel and the R program.

100 Results

101 The final sample was 77 patients. Regarding the number of
102 cases of DKA per year, the total was 11 in 2016, 13 in 2017,
103 12 in 2018, 20 in 2019, and 21 until August 2020, with an
104 average of 15.4 cases per year, with an increase of 90.9%
105 between the first and last year of the study. In those
106 patients, a similar distribution was observed between gen-
107 ders (50.6% in males, 49.4% in females). Among the evalu-
108 ated cases, 55.8% were diagnosed with a new case of T1DM.
109 The most affected age group was adolescents (54.5%).
110 Detailed data can be seen in Table 1. Figure 1 shows the fre-
111 quency of cases analyzed by age and DKA severity.

112 Regarding severity, it was classified as moderate in 37.7%
113 ($p = 0,468$) of the total, followed by severe cases in 35.1%

Table 1 General characteristics of the sample.

		Total	%
Gender	Male	39	50.6 %
	Female	38	49.4 %
Severity	Mild	21	27.3 %
	Moderate	29	37.7 %
	Severe	27	35 %
Diagnosis time	Onset	43	55.8 %
	Previous diagnosis	34	44.2 %
Age group	Infant (0–2 years old)	7	9 %
	Preschooler (2–4 years)	5	6.5 %
	School age (5–10 years old)	23	29.9 %
	Adolescents (11–16 years old)	42	54.5 %
Type of DM ^a	DM 1	75	97.4 %
	DM 2	2	2.6 %
Did they receive treatment prior to hospitalization?	Yes	42	54.6 %
	No	35	45.4 %

^a Diabetes mellitus.

114 ($p = 0,809$) and mild in 27.3% ($p = 0.279$). There was no statistically significant difference between the observed proportions for each severity level analyzed individually.

117 Comparing patients with DKA due to new-onset diabetes 118 (43 cases) to those with a previous diagnosis (34 cases), the 119 gender distribution was equal in both groups. The predominant 120 age group in the new-onset diabetes cases was school-aged 121 children (40%), whereas adolescents accounted for the majority 122 (79%) in the previously diagnosed group. The severity of DKA 123 was classified as severe in most cases in the new-onset group 124 (44%) and moderate in the decompensation group (41%). Both 125 groups exhibited high rates of

126 complications, at 80% and 70%, respectively. In the new-onset 127 group, one case (2%) required ICU admission, compared to six 128 cases (18%) in the previously diagnosed group.

129 In the sample, seven patients (9.1%) were admitted to the 130 Intensive Care Units (UCI), with 1 being moderate (3.4% of 131 moderate DKA) and 6 severe (22.2% of severe DKA). Within 132 this group, 2 required an advanced airway. Regarding the 133 moderate case, the patient’s medical records did not provide 134 justification for the ICU admission. It was a 15-year-old male 135 patient who reported discontinuing insulin use as a suicide 136 attempt. The entire management of the DKA was conducted in the 137 ICU, despite the absence of cerebral




Figure 1 Frequency of mild, moderate, and severe cases by age range.

Table 2 Conduction of treatment.

	Mean recovery time (h ^a)	Mean volume infused (ml/kg)	Mean amount of insulin (IU/kg)
Mild	5.9	44.2	0.36
Moderate	8.7	70.4	0.61
Severe	21.9	116.2	1.07
Mean	12.6	78.7	0.70
SD ^b	16.1	42.7	0.51

^a Hour.^b Standard deviation.

138 edema, need for ventilatory support, or difficult-to-control
 139 electrolyte disturbances. Only one of the patients admitted
 140 to the ICU was a case of new-onset diabetes, while the
 141 others were already known to have the disease. Three
 142 patients were female (43%) and four were male (57%). Two
 143 patients were 9 and 10 years old, while the others were ado-
 144 lescents, aged 12 to 15 years.

145 The precipitating factors for DKA cases were an infectious
 146 condition in 39% of the cases (with a predominance of respi-
 147 ratory infections in 69%), poor adherence to treatment in
 148 previously diabetic patients in 21% of the cases, and no
 149 acute cause identified in 40%. Among patients who already
 150 had a diagnosis of diabetes, failure to use insulin was the
 151 cause in 47% of cases of DKA.

152 The average time between the onset of symptoms and
 153 the diagnosis of DKA was 11.8 (\pm 16.4) days. The mean for
 154 DKA recovery time was 12.6 (\pm 16.1) hours, and the mean
 155 volume of infused solution was 78.7 (\pm 42.7) ml/kg. An
 156 increase in the insulin dosage and in the time to recovery
 157 was observed according to the greater severity of the cases,
 158 as shown in Table 2.

159 The use of bicarbonate was identified in 53.8% of severe
 160 cases and 27.6% of moderate cases, and it was not used for
 161 mild cases.

162 It was investigated the following complications: hypoka-
 163 lemia, hypoglycemia, cerebral edema, and death. The pro-
 164 portion of occurrence of each one of them, considering the
 165 total sample, and the proportion according to severity, can
 166 be seen in Table 3.

167 Hypokalemia was the most frequent complication during
 168 treatment, occurring in 54.5% of cases, and occurring in
 169 81.5% of severe DKA. Hypoglycemia (values below 70 mg/
 170 dL) occurred in 20.8% of cases, with a similar distribution
 171 according to severity.

172 Regarding hypophosphatemia, inorganic phosphorus lev-
 173 els were found in only 33.8% of admissions. Within this per-
 174 centage, there were 21 cases of hypophosphatemia (80.8%).

175 The occurrence of cerebral edema (all confirmed by head
 176 computed tomography) was found in 11.7% of the total
 177 (9 patients), being more frequent in severe cases. It was found
 178 that 40.2% of children had neurological symptoms during DKA
 179 correction, and of these, 29% received confirmation of edema
 180 by imaging. The symptoms of cerebral edema presented were
 181 drowsiness (100% of cases), alteration in the Glasgow Coma
 182 Scale (88.9% of cases), headache (44.5%), hyporesponsiveness
 183 (44.5%), dizziness (11%), and agitation (11%).

184 Cerebral edema was the cause of the only death, corre-
 185 sponding to an overall DKA mortality of 1.3%. Considering
 186 mortality only among cases of edema, this corresponds to
 187 11.1%.

Discussion

188 Over the study period, the authors observed a significant
 189 increase in DKA cases, with nearly double the number of
 190 cases reported in 2020 compared to 2016, especially consid-
 191 ering that the cases analyzed in 2020 are only up to August.
 192 This trend aligns with global studies indicating rising DKA
 193 incidence, such as reports from Germany, China, Chile, and
 194 Croatia.⁸⁻¹¹ Potential factors contributing to this increase
 195 include delayed diagnosis, limited public awareness of T1DM
 196 symptoms, and healthcare access challenges exacerbated
 197 by systemic inequalities.¹²

199 Among the cohort, 55.8% of DKA cases occurred in newly
 200 diagnosed T1DM patients, consistent with other Brazilian
 201 studies reporting rates between 41% and 59.6%.¹³⁻¹⁵ Data
 202 from the world literature show a wider variation: it ranges
 203 from 32% to 67.4%.^{9,11,16-18} Such variability is related to the
 204 incidence of type 1 diabetes in each region and public health
 205 initiatives for population education for early recognition of
 206 disease symptoms.¹⁰

207 Regarding the age group (Table 1), the authors identified
 208 most cases in adolescents (11–16 years, 54.5%), mostly

Table 3 Occurrence of complications according to the severity of the symptoms.

Severity of the DKA ^a :	Hypokalemia		Hypoglycemia		Cerebral edema		Death	
	Occurrences	%	Occurrences	%	Occurrences	%	Occurrences	%
Mild	7	33.3%	4	19.1%	0	0	0	0
Moderate	13	44.8%	6	20.7%	2	6.9%	0	0
Severe	22	81.5%	6	22.2%	7	25.9%	1	3.7%
Total	42	54.5%	16	20.8%	9	11.7%	1	1.3%

^a DKA, diabetic ketoacidosis.

with mild symptoms, like studies in Paraguay (57.9% in adolescents).⁶ A greater number of cases of DKA was also found in adolescents who already had a diagnosis of type 1 diabetes in a Chilean study, associated with poor adherence to treatment¹¹; in Venezuela, cases in previously diabetic patients were also higher in the 10–19 age group.¹⁶ This contrasts with severe DKA being more prevalent among school-aged children (Figure 1), likely due to delays in diagnosis related to nonspecific symptoms.

In this series, 64% of the cases of adolescents already had a diagnosis of type 1 diabetes. From this number, 49% presented a lack of adequate use of insulin as the cause of DKA, even with clinical follow-up in specific outpatient clinics and free medication for treatment. Among the other age groups with a previous diagnosis of diabetes, only 16% of DKA were due to poor adherence to therapy.

The present findings indicate that recovery times for DKA in the studied institution (mean 12.6 h) exceed those reported by the International Society for Pediatric and Adolescent Diabetes (ISPAD) (mean 11.6 h),¹⁹ especially in more severe cases (Table 2). In other Brazilian series, the authors found an average for recovery ranging from 11 to 27 h,^{14,15} with a difference in the time for DKA resolution considering the normalization of pH and bicarbonate individually, with an average of 18 h for the first and 21 h for the second.¹⁵ In other countries, it takes about 14 to 29 h to correct DKA.^{10,20,21}

This discrepancy may reflect differences in treatment criteria. The protocol requires both $\text{pH} \geq 7.3$ and bicarbonate $\geq 15 \text{ mEq/L}$ to define resolution, while others take into account only one or the other.^{3,10,22}

Prolonged treatment time is directly associated with the use of larger volumes of hydration and insulin, which can lead to the appearance of complications such as hypoglycemia and hypokalemia. In comparison with a study in Campinas (São Paulo, Brazil) in which the total volume used for the treatment of severe cases was on average 82.7 ml/kg in moderate cases and 71.4 ml/kg in mild cases,¹⁵ in this service the total volume needed was lower in mild and moderate cases (44.1 and 70.4 respectively), and higher in severe cases (116.2 ml/kg).

Regarding the use of insulin, there was a greater need for insulin therapy, the greater the severity of the case. This finding is similar to the study carried out in Campinas, in which the time of insulin administration was directly proportional to the severity of the cases.¹⁵ However, the institutional protocol makes use of subcutaneous regular insulin every hour for the treatment of DKA, unlike other evaluated studies.^{14,15,23}

As for the use of sodium bicarbonate, its use is not routinely recommended.^{3,18,23,24} Studies have not shown benefit from the administration of bicarbonate, with its use being suggested only in cases of severe acidosis ($\text{pH} < 6.9$) associated with cardiac alteration or life-threatening hyperkalemia.³ Its use was carried out in 0.04% of hospitalizations in Campinas, all of which were severe cases of patients in the Intensive Care Units who did not respond to the initial treatment.¹⁵ In the study carried out in Paraguay, it was used in 5% of the cases.²⁰ In this work, higher use was identified in moderate and severe cases refractory to initial treatment.

Regarding complications, hypokalemia was the most frequent complication (Table 3). In other study from Brazil, 34.6% of the patients had hypokalemia.¹⁴ In worldwide

data, the frequency of hypokalemia ranged from 22% to 67,1%.^{11,25–28} Research suggests that the use of lower doses of insulin leads to a lower risk of developing hypokalemia.²⁸

Hypoglycemia was the second most common complication found in this work, occurring in 20.8% of cases. In other Brazilian studies, the rate was lower, ranging from 13.1% to 15%.^{14,15} The authors must consider that the difference in the frequency of hypoglycemia between the services may be due to the use of different cuts for its definition; in this protocol, it is defined as values below 70 mg/dL. Studies show the occurrence of hypoglycemia in about 25% of DKA treatments using high doses of insulin and indicate that this frequency could decrease with continuous insulin infusion at lower doses.²⁶

Hypophosphatemia is a disorder little researched in the service, and that may be underdiagnosed. However, there is no clinical proof of benefit in the treatment with its replacement.³

In the present data, the authors found an ICU admission rate of 9.1% among all cases and an admission rate of 22% when considering only severe cases. ISPAD recommends ICU admission for all severe DKA cases or those at high risk for cerebral edema. However, there is limited published data on ICU admission rates for children during DKA treatment. A recent publication by an Italian group reported a total ICU admission rate of 10% in severe DKA cases.²⁹ Meanwhile, another recent monocentric study from Croatia showed bigger rates.¹⁰ Discrepancies in DKA-related hospitalization rates may be influenced by unequal access to PICU resources across regions or by differences in the proficiency of DKA management in non-intensive pediatric care units.

The occurrence of cerebral edema reported by ISPAD ranges from 0.5 to 0.9%.³ In this study, the authors found a rate of 11.7%, which is considered high. In other recent publications in Brazil, the frequency of cerebral edema ranged from 1.24% to 5.7%.^{13–15} In other countries, it ranged between 1.2% and 13.2%.^{10,21,25}

According to ISPAD, the number of deaths due to DKA in children ranges from < 1% in developed countries to 3–13% in developing countries, and from 21% to 24% among those with cerebral edema.³ In this research, among all patients, the authors found a death rate of 1.3%, which was higher than reported by current guidelines. Regarding mortality among cases with cerebral edema, the rate found was 11%, lower than that reported by ISPAD. In other Brazilian studies, it ranged from 0.62% to 2% of the total of patients.^{13–15} In Campinas, it corresponded to 100% among cases with cerebral edema.¹⁵ In other countries, the frequency of deaths ranged between 0.6% and 13.2% of the total patients, and, from this total, 15%–33.5% occurred due to cerebral edema.^{10,21,26}

The objective of this study was to characterize the pediatric population with DKA at HC-FMRP and its complications. Increasing DKA incidence rates were observed, consistent with other studies in Brazil and worldwide. Adolescents, many with previously diagnosed diabetes, were the most affected, highlighting adherence difficulties. Cerebral edema rates were higher than expected, but mortality was lower, emphasizing the need for preventive measures.

Further studies are necessary to explore the 2020 DKA increase and confirm its continuity. Complication data from this study can guide improvements in protocols, focusing on reducing hypoglycemia and hypokalemia. Notably, the low mortality rate among cerebral edema cases suggests

333 subcutaneous insulin is a viable alternative where intrave-
334 nous pumps are unavailable.

335 The study's limitations include retrospective analysis of
336 non-standardized medical records, which complicates data
337 collection. Additionally, patients often receive external
338 treatment that lacks detailed records, affecting the assess-
339 ment of pre-hospitalization therapeutic measures. While the
340 study's sample size of 77 patients may be low, the HC-FMRP
341 serves as a regional reference for pediatric endocrinology,
342 enabling the collection of numerous cases and allowing for
343 protocol evaluation with other global guidelines. Despite
344 these challenges, the study's findings provide critical insights
345 into local DKA management and allow actionable improve-
346 ments in treatment protocols, including optimizing hydration
347 strategies, insulin dosing, and complication monitoring.

348 Funding

349 This research did not receive any specific grant from funding
350 agencies in the public, commercial, or not-for-profit sectors.

351 Conflicts of interest

352 The authors declare no conflicts of interest.

353 Editor

354 C. de A.D Alves

355 References

- 356 1. Magliano D, Boyko EJ. IDF Diabetes Atlas. 10th edition. Brussels:
357 International Diabetes Federation; 2021.
- 358 2. Vencio SC. Diretrizes Da Sociedade Brasileira De Diabetes 2019-
359 2020. Editora Clannad; 2019.
- 360 3. Glaser N, Fritsch M, Priyambada L, Rewers A, Cherubini V,
361 Estrada S, et al. ISPAD Clinical Practice Consensus Guidelines
362 2022: diabetic ketoacidosis and hyperglycemic hyperosmolar
363 state. *Pediatr Diabetes*. 2022;23:835–56.
- 364 4. Negrato CA, Cobas RA, Gomes MB. Brazilian Type 1 Diabetes
365 Study Group. Temporal changes in the diagnosis of type 1 diabe-
366 tes by diabetic ketoacidosis in Brazil: a nationwide survey. *Diab-
367 et Med*. 2012;29:1142–7.
- 368 5. Carlotti AP, Carmona F. Cetoacidose diabética. Rotinas Em Tera-
369 pia Intensiva Pediátrica. São Paulo: Blucher; 2015;1:141–9.
- 370 6. Castellanos L, Tuffaha M, Koren D, Levitsky LL. Management of
371 diabetic ketoacidosis in children and adolescents with type 1
372 diabetes mellitus. *Pediatr Drugs*. 2020;22:357–67.
- 373 7. Wells RH, Bay-Nielsen H, Braun R. CID-10: Classificação Estatís-
374 tica Internacional De Doenças e Problemas Relacionados à
375 Saude (2011). São Paulo: EDUSP; 2011, Vol. 3v.
- 376 8. Ziegler R, Neu A. Diabetes in childhood and adolescence. *Dtsch
377 Ärztbl Int*. 2018;115:146–56.
- 378 9. Peng W, Yuan J, Chiavaro V, Dong G, Huang K, Wu W, et al. 10-
379 year incidence of diabetic ketoacidosis at type 1 diabetes diag-
380 nosis in children aged. 16 years from a large regional center
381 (Hangzhou, China). *Front Endocrinol*. 2021;12:653519.
- 382 10. Lah Tomulić K, Matko L, Verbić A, Milardović A, Severinski S,
383 Kolić I, et al. Epidemiologic characteristics of children with dia-
384 betic ketoacidosis treated in a pediatric intensive care unit in a

- 10-year-period: single centre experience in Croatia. *Medicina* 385
(Mex). 2022;58:638. 386
11. Del Pozo P, Aránguiz D, Córdova G, Scheu C, Valle P, Cerda J, 387
et al. Perfil clínico de niños con cetoacidosis diabética en una 388
Unidad de Paciente Crítico. *Rev Chil Pediatría*. 2018;89:491–8. 389
12. Zucchini S, Bonfanti R, Schiaffini R, Passanisi S, Salzano G, Lom- 390
bardo F. Editorial: diabetic ketoacidosis in children and adoles- 391
cents: from epidemiological data to clinical aspects. *Front 392
Pediatr*. 2023;11:1164946. 393
13. Souza LC, Kraemer GD, Koliski A, Carreiro JE, Cat MN, Lacerda 394
LD, et al. Diabetic ketoacidosis as the initial presentation of 395
type 1 diabetes in children and adolescents: epidemiological 396
study in southern Brazil. *Rev Paul Pediatr*. 2020;38:e2018204. 397
14. Lopes CL, Pinheiro PP, Barberena LS, Eckert GU. Diabetic ketoa- 398
cidosis in a pediatric intensive care unit. *J Pediatr (Rio J)*. 2017; 399
93:179–84. 400
15. Castro L, Morcillo AM, Guerra-Junior PD. Diabetic ketoacidosis 401
in children: treatment profile at a university hospita. *Rev Assoc 402
Med Bras*. 2009;54:548–53. 403
16. Villarreal Y, Briceño Y, Paoli M. Diabetes mellitus tipo 1: caracte- 404
rísticas clínicas y demográficas en pacientes del servicio de endo- 405
crinología del instituto autónomo hospital universitario de los 406
andes, mérida, venezuela. *Rev Venez Endoc*. 2015;13:33–47. 407
17. Alonso GT, Coakley A, Pyle L, Manseau K, Thomas S, Rewers A. 408
Diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado 409
children, 2010–2017. *Diabetes Care*. 2020;43:117–21. 410
18. Lapolla A, Amaro F, Bruttomesso D, Di Bartolo P, Grassi G, Maf- 411
feis C, et al. Diabetic ketoacidosis: a consensus statement of 412
the Italian Association of Medical Diabetologists (AMD), Italian 413
Society of Diabetology (SID), Italian Society of Endocrinology 414
and Pediatric Diabetology (SIEDP). *Nutr Metab Cardiovasc Dis*. 415
2020;30:1633–44. 416
19. Wolfsdorf JI, Glaser N, Agus M, Fritsch M, Hanas R, Rewers A, 417
et al. ISPAD Clinical Practice Consensus Guidelines 2018: dia- 418
betic ketoacidosis and the hyperglycemic hyperosmolar state. 419
Pediatr Diabetes. 2018;19:155–77. 420
20. Alviso López RD, Blanco Espínola CF. Evolución clínico-laborator- 421
ial de la cetoacidosis diabética en pacientes con diagnósticos 422
de diabetes tipo I, ingresados a la Urgencia Pediátrica del Hospi- 423
tal de Clínicas. *Pediatría Asunción*. 2015;42:198–204. 424
21. Bui TP, Werther GA, Cameron FJ. Trends in diabetic ketoacidosis 425
in childhood and adolescence: a 15-yr experience: DKA admis- 426
sions: trends over 15 yr. *Pediatr Diabetes*. 2002;3:82–8. 427
22. Jiménez Fadul AM, Cortés Millán JC. Enfoque diagnóstico y ter- 428
apéutico de la cetoacidosis diabética en niños y adolescentes 429
en el servicio de urgencias. *Iatreia*. 2013;26:325–35. 430
23. Cashen K, Petersen T. Diabetic ketoacidosis. *Pediatr Rev*. 2019; 431
40:412–20. 432
24. Dhatariya KK, Glaser NS, Codner E, Umpierrez GE. Diabetic 433
ketoacidosis. *Nat Rev Dis Primer*. 2020;6:40. 434
25. González NC, Raga MG, Zaldívar DN, González LL. Cetoacidosis 435
diabética en niños menores de 15 años. *Rev Cub Med Gen Int*. 436
2014;30:93–102. 437
26. Jayashree M, Singhi S. Diabetic ketoacidosis predictors of out- 438
come in a pediatric intensive care unit of a developing country. 439
Pediatr Crit Care Med. 2004;5:427–33. 440
27. Dhatariya KK, Nunney I, Higgins K, Sampson MJ, Icton G. 441
National survey of the management of diabetic ketoacidosis 442
(DKA) in the UK in 2014. *Diabet Med*. 2016;33:252–60. 443
28. Pasquel FJ, Tsegka K, Wang H, Cardona S, Galindo RJ, Fayfman 444
M, et al. Clinical outcomes in patients with isolated or com- 445
bined diabetic ketoacidosis and hyperosmolar hyperglycemic 446
state: a retrospective, hospital-based cohort study. *Diabetes* 447
Care. 2020;43:349–57. 448
29. Passanisi S, Salzano G, Basile P, Bombaci B, Caime F, Rulli I, 449
et al. Prevalence and clinical features of severe diabetic ketoa- 450
cidosis treated in pediatric intensive care unit: a 5-year mono- 451
centric experience. *Ital J Pediatr*. 2023;49:58. 452